Robinswood Financial’s Atossa Therapeutics ATOS Stock Holding History

Robinswood Financial’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-170	Closed	-$894	–	430
2026 Q1	$894	Hold	170	–	–	﹤0.01%	384
2025 Q4	$1.51K	Buy	+170	New	+$2.15K	﹤0.01%	353

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Robinswood Financial's ATOS Position: Q2 2026 in Review

Robinswood Financial sold out of Atossa Therapeutics (ATOS) in Q2 2026, closing a stake of 170 shares — an estimated $894 sold.

Robinswood Financial first reported a position in ATOS in Q4 2025 and held it in 2 quarters. The position peaked at $1.51K in Q4 2025. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

Robinswood Financial reported no remaining Atossa Therapeutics position as of Q2 2026 after selling out during the quarter.
Robinswood Financial sold 170 Atossa Therapeutics shares in Q2 2026, an estimated $894.
Robinswood Financial first reported a position in Atossa Therapeutics in Q4 2025 and held it in 2 quarters.
Robinswood Financial's Atossa Therapeutics position peaked at $1.51K in Q4 2025.
31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Robinswood Financial's 13F filing for Q2 2026, filed 15 Jul 2026.